Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 16;6(1):27-33.
doi: 10.1002/mdc3.12682. eCollection 2019 Jan.

A Nationwide Survey of Parkinson's Disease Medicines Availability and Affordability in Nigeria

Njideka U Okubadejo  1 , Oluwadamilola O Ojo  1 , Kolawole W Wahab  2 , Sani A Abubakar  3 , Olugbo Y Obiabo  4 , Fatai K Salawu  5 , Ernest O Nwazor  6 , Osigwe P Agabi  1 , Olajumoke O Oshinaike  7
Affiliations

A Nationwide Survey of Parkinson's Disease Medicines Availability and Affordability in Nigeria

Njideka U Okubadejo et al. Mov Disord Clin Pract. .

Abstract

Background and objectives: Limited access to medicines can impact negatively on outcomes in people with Parkinson's disease (PD). The study objectives were to determine the availability and assess the affordability of antiparkinsonian medications in pharmacies across Nigeria.

Methods: This was a cross-sectional nationwide study utilizing the World Health Organization/Health Action Initiative methodology. Strategically selected private- and public-sector pharmacies in the six geopolitical zones of Nigeria were surveyed for availability of medicines for management of early and advanced PD. The nine categories were: levodopa/peripheral decarboxylase inhibitors, dopamine receptor agonists, monoamine oxidase type B inhibitors, anticholinergics, catechol-o-methyl transferase inhibitors, atypical antipsychotics, antidepressants, antidementia drugs, and miscellaneous (e.g., drugs for orthostatism, urinary incontinence, and sleep disturbance). Unaffordability was defined as paying more than 1 days' wages (>N600 or > US$1.67) for a standard 30-day supply.

Results: One hundred twenty-three pharmacies were surveyed (62 private [50.4%] and 61 public sector [49.6%]; range of 15-25 pharmacies in each geopolitical zone). Private exceeded public-sector availability across all nine categories of PD medicines (P < 0.05). The most available medicines were dopamine receptor agonists (68.3%; predominantly ergot-derived bromocriptine), anticholinergics (56.1%; mainly trihexyphenidyl), and l-dopa formulations (48%; mainly 250/25 l-dopa/carbidopa). Only two medications (trihexyphenidyl tablets and biperiden injection) were affordable. The average number of day's minimum wages for a 30-day supply of PD medicines was 41.3 days (range, 1-371).

Conclusions: PD medicines access is limited in Nigeria. Strategies, including engagement of stakeholders to consider interventions to improve and prioritize PD medicines access, are urgently warranted.

Keywords: Africa; Nigeria; Parkinson's disease; affordability; availability; medicines access.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization . Neurological Disorders: Public Health Challenges. Geneva, Switzerland: World Health Organization; 2006.
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990‐2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. - PMC - PubMed
    1. World Health Organization . Atlas: Country Resources for Neurological Disorders, 2nd ed. Geneva, Switzerland: World Health Organization; 2017. Licence: CC BY‐NC‐SA 3.0 IGO.
    1. United Nations Department of Economic and Social Affairs, Population Division . World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.241. New York, NY: United Nations; 2015.
    1. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143–2146. - PubMed

LinkOut - more resources